OPKO Health Inc

OPK has decisively broken below key support on elevated volume, confirming a bearish medium-term bias driven by a Support Failure pattern and EMAs crossing lower. Price is extended below its short-term EMAs, making immediate selling unfavorable. Optimal execution is to wait for a corrective rally into the fallen EMAs or prior support-turned-resistance before initiating new short positions. Long-term downtrend remains intact under a declining 200 SMA.

• ↑Ended Q1 with $341M cash funding R&D and a $108M share repurchase
• ↑Regeneron deal offers non-dilutive milestone payments exceeding $1B
• ↓Negative earnings yield and elevated leverage indicate financial strain